Cerebral atrophy in an infant following treatment with ifosfamide

Bruggers, Carol S.; Friedman, Henry S.; Tien, R D; DeLong, Robert

doi:10.1002/mpo.2950230412

Cited by 14 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, CDDP could enhance IFO‐mediated nephrotoxicity . Therefore, it has been speculated that IIE development is likely induced by high levels of metabolites of IFO, including chloroacetaldehyde, owing to renal dysfunction, caused by a combination of multiple drugs with known nephrotoxicity …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of the clinical characteristics of pediatric patients who experience ifosfamide‐induced encephalopathy

Ide

Yanagisawa

Kubota

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Several kinds of pediatric hematological and/or malignant diseases are treated with chemotherapy regimens including ifosfamide (IFO). IFO‐induced encephalopathy (IIE) is one of the serious side effects, but there is not enough evidence regarding the clinical features of IIE in children. Procedure We performed a retrospective study on pediatric patients treated with chemotherapy regimens, including IFO, at a single center. We recorded the clinical characteristics of all patients; we compared the clinical characteristics between patients who developed IIE and those who did not. Results In total, 88 patients received a chemotherapy regimen including IFO. IIE developed in seven patients (8.0%). The median age of patients at the time of IIE development was 4.3 (range 1.4‐6.5) years in the younger population. Six of seven patients with IIE improved with supportive therapy only; however, one patient died due to heart failure. Overall survival was not different between the two groups. Multivariable analysis revealed that the co‐administration of cisplatin (CDDP) or carboplatin (CBDCA) was a significant risk factor associated with IIE. Although there was no significant difference in laboratory data between the groups before chemotherapy, patients who developed IIE showed exacerbation in several laboratory tests, including those for renal and liver functions. Conclusions Renal dysfunction caused by the combination of nephrotoxic agents (IFO and CDDP/CBDCA) seems to be important for the development of pediatric IIE. It was thought to be difficult to predict IIE onset based on laboratory data before the initiation of chemotherapy regimens; however, careful observation of laboratory data during IFO chemotherapy regimens may help predict IIE onset and facilitate early treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Neurologic toxicity can be caused by IFO administration, even in the pediatric population . Some gene polymorphisms might be associated with pediatric IIE onset; however, there are few studies on the analysis of clinical characteristics, such as patient background and/or laboratory data, and IIE development in children.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the clinical characteristics of pediatric patients who experience ifosfamide‐induced encephalopathy

Ide

Yanagisawa

Kubota

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…The occurrence of a progressive encephalopathy, resulting in brain atrophy in one case and in subacute CNS degeneration leading to death in another, have been reported in 2 children after a high-dose IFOS regimen [30, 31]. …”

Section: Ifosfamide Neurotoxicity: Signs and Symptomsmentioning

confidence: 99%

Neurological Toxicity of Ifosfamide

Nicolao

Giometto²

2003

Oncology

View full text Add to dashboard Cite

Ifosfamide is an alkylating agent with well-demonstrated efficacy against a large number of malignant diseases. With cyclophosphamide it shares a toxicity profile characterized by myelosuppression and urotoxicity, but ifosfamide has additionally disclosed adverse neurological effects. Ifosfamide-related central nervous system toxicity is characterized by metabolic encephalopathy of varying severity. Symptoms have been reported in 5–30% of all patients treated with ifosfamide. The mechanism of ifosfamide-related central nervous system toxicity has not been fully elucidated, although the symptoms have most often been noted when the drug is given at high doses or administered orally. The neurotoxicity is generally self-limiting and reversible between 48 and 72 h after discontinuation of ifosfamide, although fatal sequelae have been reported. Therapeutic options are now available.

show abstract

“…All these agents have been followed by long-term sequelae. Ifosfamide has been connected with neurotoxicity [3]. We could demonstrate early after the start of ifosfamide in the treatment of rhabdomyosarcoma renal and tubular dysfunction, leading to a syndrome known as the Toni-Fanconi syndrome [2].…”

Section: Discussionmentioning

confidence: 99%

Paratesticular rhabdomyosarcoma

Vries

1995

World J Urol

View full text Add to dashboard Cite

Even though rhabdomyosarcoma is the most common soft tissue sarcoma in children, accounting for 5-10% of all malignant disease in children under 15 years of age, so few cases are seen in a single institution that only the combined efforts of multicentre prospective trials made it possible fro adequate treatment schedules to be devised. Thank to this cooperation, survival rates have increased dramatically in recent decades; risk factors have been identified and treatment can now be adapted accordingly. This is especially true for the paratesticular rhabdomyosarcoma (PTRM), which now has a good prognosis in all stages. The striking similarity of tumor behavior and metastatic pathways to those in germ-cell tumors in young male adults can provide us with more extensive data derived from a much larger group of patients. Recent data are gathered and evaluated in this review. Only in this way will it be possible to eliminate all treatment modalities known to be followed by severe sequelae, thus avoiding exposure of the patients to a therapy that carries more risks than the primary tumor itself.

show abstract

Cerebral atrophy in an infant following treatment with ifosfamide

Cited by 14 publications

References 17 publications

Analysis of the clinical characteristics of pediatric patients who experience ifosfamide‐induced encephalopathy

Analysis of the clinical characteristics of pediatric patients who experience ifosfamide‐induced encephalopathy

Neurological Toxicity of Ifosfamide

Paratesticular rhabdomyosarcoma

Contact Info

Product

Resources

About